Sonova Holding AG (0QPY) Share Price & Analysis
0QPY Stock Chart & Stats
- Day’s Range
- CHF 279.60 - CHF 285.10
- 52-Week Range
- CHF 163.20 - CHF 286.30
- Previous Close
- CHF 281.94
- Volume
- 51.96K
- Average Volume (3M)
- 31.00K
- Market Cap
- CHF 16.33B
- Enterprise Value
- CHF 11.68B
- Total Cash (Recent Filing)
- CHF 722.10M
- Total Debt (Recent Filing)
- CHF 1.71B
- Price to Earnings (P/E)
- 39.3
- Beta
- 1.15
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- 4.57
- Last Dividend Ex-Date
- Jun 19, 2026
- Dividend Yield
- 1.66%
Bulls Say, Bears Say
Bulls Say
Hearing Instruments Growth And Margin Expansion
The core Hearing Instruments segment is growing faster than its revenue base while expanding profitability, indicating operating leverage and strong product economics. Sustained margin gains can strengthen reinvestment capacity, support innovation, and improve earnings resilience over the next several quarters.
Product Innovation And Market-Share Gains
Sonova is using differentiated technology and a broad product pipeline to support adoption and win share, rather than relying only on market expansion. AI-enabled devices, rechargeable products, and connectivity can reinforce its competitive position and support future upgrade cycles.
Strong Cash Generation And Capital Discipline
High cash conversion means reported earnings are being translated into funding that can support product development, retail expansion, acquisitions, and shareholder returns. Disciplined capital spending and stable working capital also improve Sonova's ability to pursue growth without excessive financial strain.
Bears Say
Cochlear Implants Underperformance
The Cochlear Implants business is facing weaker system and upgrade demand alongside competitive pressure and reimbursement changes in China. Persistent weakness would dilute group growth, reduce segment profitability, and make consolidated performance more dependent on the hearing-aid franchise.
Regulatory And Execution Risk For CI Recovery
Recovery in Cochlear Implants depends partly on a planned processor launch whose timing is not fully controlled by management. Regulatory delays could prolong weak upgrade activity, defer expected growth, and increase the risk that competitive pressure remains elevated through the next several quarters.
Foreign-Exchange Pressure On Reported Results
Currency movements are reducing the translation of underlying operating performance into reported Swiss-franc results. If exchange rates remain unfavorable, they can suppress reported revenue and EBIT growth, limit visible margin improvement, and complicate comparisons despite healthy constant-currency execution.
Sonova Holding AG News
0QPY FAQ
What was Sonova Holding AG’s price range in the past 12 months?
What is Sonova Holding AG’s market cap?
When is Sonova Holding AG’s upcoming earnings report date?
How were Sonova Holding AG’s earnings last quarter?
Is Sonova Holding AG overvalued?
Does Sonova Holding AG pay dividends?
What is Sonova Holding AG’s EPS estimate?
How many shares outstanding does Sonova Holding AG have?
What happened to Sonova Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sonova Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sonova Holding AG
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Eric Alain Bernard
- Employees
- 18,580
- Website
- www.sonova.com
- Address
- Laubisrutistrasse 28, Stäfa, ZH, 8712, CH
Sonova Holding AG (0QPY) Earnings & Revenues
0QPY Earnings Call
Earnings Call SentimentPositive
The call presented a clearly positive operational and financial picture: above-market sales growth, strong wholesale momentum and market-share gains, significant margin expansion, robust cash conversion and a confident guidance range. Key negatives are concentrated in the Cochlear Implants business (declining sales and margins), substantial non‑recurring charges and FX headwinds, and timing/regulatory risk around the planned CI product launch. On balance, the company showed broad-based momentum and multiple levers (product pipeline, retail M&A, efficiency initiatives) to drive future growth, outweighing the identified headwinds.
View all GB:0QPY earnings summaries0QPY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |









